MultiplexDX International diagnosed 78 oncological patients in August using its Multiplex8+ diagnostic test.
Published
Signal category
Customers & Market
Quote
“Počas augusta sme napokon zdiagnostikovali až 78 onkologických pacientiek.”
— Pavol Cekan|MultiplexDX International team
Company
MultiplexDX International
Eliminating cancer misdiagnosis by launching a new diagnostic test in 2023 and operating a boutique oligo house.
- Industry
- Biotechnology Research
- Location
- Rockville, US
- Company size
- 44 employees
MultiplexDX is an international corporation established in 2015 consisting of two units: MultiplexDX Inc. located in Maryland US and MultiplexDX s.r.o. located in Slovakia. Our main goal is to eliminate cancer misdiagnosis by launching 98% accurate, quantitative and accessible diagnostic tests. We also operate a boutique oligohouse offering highly specialized custom oligonucleotides to the research community. Our mission: By transforming breast cancer treatment non-responders into responders and ensuring durable responses, we aim to drastically increase survival rates by at least 50%. Objectives of the company are: i) development of the technologies and the products for molecular diagnostic markets superior to currently available products; ii) core facility service using proprietary Multiplex TM technology iii) development of hi-tech 3D digital pathology services. Find out more about MultiplexDX on our official website and in social media: http://www.multiplexdx.com/ https://www.facebook.com/multiplexdx/ https://twitter.com/@multiplexdx http://bit.ly/MDXGooglePlus https://www.youtube.com/c/multiplexdx
Founded 2015